Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY) increase in global sales, reaching USD 6.5 billion. This growth comes despite a 3% decrease in net selling price, primarily fueled by an impressive 11% increase in volume. Notably, this marks the company’s fourth consecutive quarter of double-digit volume growth.
Among Amgen’s key global products, several exhibited remarkable double-digit YOY growth during the three-month period. The bispecific T-cell engager (BiTE) Blincyto (blinatumomab) led the pack with a 55% increase, followed closely by Evenity (romosozumab) at 53%, Nplate (romiplostim) at 45%, and Repatha (evolocumab) at 31%. Other notable performers included the Humira biosimilar Amgevita (adalimumab) at 30%, Prolia (denosumab) at 14%, and Kyprolis (carfilzomib) at 10%.
In the U.S., Amgen’s operations generated USD 4.7 billion in revenue during the third quarter, driven by an 11% YOY volume growth. Meanwhile, international sales totaled USD 1.9 billion, reflecting a 12% volume growth, with the Asia Pacific region experiencing a remarkable 27% increase.
During the earnings call, Amgen Vice President Justin Claeys highlighted that the reported figures do not include any contributions from the recently acquired Horizon Therapeutics, a specialist in rare diseases, as the acquisition was finalized only recently.-Fineline Info & Tech
